Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676963 | 0.96 | PDE9A (0.34) | HRH1PDE9APDK2PDE4APDE4B | |
| SCHEMBL677024 | 0.94 | PDE9A (0.36) | HRH1PDE9APDK2PDE4APDE4B | |
| SCHEMBL2921894 | 0.94 | PDE9A (0.36) | HRH1PDE9APDK2PDE4APDE4B | |
| SCHEMBL233125 | 0.94 | PDE9A (0.36) | HRH1PDE9APDK2PDE4APDE4B | |
| SCHEMBL709427 | 0.92 | HRH1 (0.35) | HRH1 | |
| SCHEMBL677022 | 0.90 | HRH1 (0.32) | HRH1 | |
| SCHEMBL4352771 | 0.89 | HRH1 (0.30) | HRH1 | |
| SCHEMBL6530733 | 0.86 | PDE9A (0.35) | PDE9APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL677299 | 0.86 | PDE9A (0.30) | PDE9A | |
| SCHEMBL6532492 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399445-A2 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-24 | — | — | EP | claimed |
| EP-1343791-A2 | SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | claimed |
| WO-2002059129-A2 | SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | claimed |
| WO-2002059124-A2 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | claimed |
| US-11739070-B2 | C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-08-29 | — | — | US | disclosed |
| US-11685729-B2 | C5a receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-06-27 | — | — | US | disclosed |
| US-20210122736-A1 | C5A RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2021-04-29 | — | — | US | disclosed |
| EP-3740476-A1 | C5A RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| EP-3740477-A1 | C5A RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| US-20200347029-A1 | C5A RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-11-05 | — | — | US | disclosed |
| CN-111683937-A | C5a receptor modulators | 爱杜西亚药品有限公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111615513-A | C5a receptor modulators | 爱杜西亚药品有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-1343791-A2 | SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| WO-2002059129-A2 | SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059127-A2 | PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1189905-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000077001-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347029-A1 | C5A RECEPTOR MODULATORS | C5AR1, C3AR1, C5AR2 | HRH1 128/4885PARP10 689/4885PDE9A 1400/4885 |
| US-20210122736-A1 | C5A RECEPTOR MODULATORS | C5AR1, C3AR1, C5AR2 | HRH1 119/4885PARP10 613/4885PDE9A 1608/4885 |
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | HRH1 1377/4885PARP10 3260/4885PDE9A 1949/4885 |
| US-11685729-B2 | C5a receptor modulators | C5AR1, C3AR1, C5AR2 | HRH1 119/4885PARP10 613/4885PDE9A 1608/4885 |
| US-11739070-B2 | C5A receptor modulators | C5AR1, C3AR1, C5AR2 | HRH1 128/4885PARP10 689/4885PDE9A 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.